1093880-37-5Relevant articles and documents
Synthesis of phantasmidine
Zhou, Quan,Snider, Barry B.
, p. 526 - 529 (2011)
Reaction of 6-chloro-2-fluoro-3-pyridineacetamide with 1,2- bis(trimethylsilyloxy)cyclobutene in ether saturated with hydrogen chloride afforded the keto amide in 85% yield. In the key step, treatment of the keto amide with aqueous KOH in t-BuOH resulted in a tandem intramolecular aldol reaction-intramolecular nucleophilic aromatic substitution sequence to give the tetracylic lactam in 46% yield. Reduction of the lactam with BH3 in THF gave phantasmidine in 67% yield.
TRICYCLIC PIPERIDINE COMPOUNDS
-
Page/Page column 75-76, (2016/11/21)
The present invention relates to compounds of the formula (I) wherein R1a, R1b, R2, R3, (R4)n and ring (A) are as described in the description, to their preparation, to pharmaceutically acc
TRICYCLIC PIPERIDINE COMPOUNDS
-
Page/Page column 112-113, (2015/06/08)
The present invention relates to compounds of the formula (I), wherein R, R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.
Mosher's amide-based assignment of the absolute configuration of phantasmidine
Zhou, Quan,Snider, Barry B.
, p. 779 - 787 (2016/10/30)
The absolute configuration of phantasmidine was assigned by analysis of the two conformers of the two Mosher amides. The expected shielding of the protons adjacent to the nitrogen and large long range shielding (~1 ppm) of the cyclobutane methylene protons in 16major and the pyridine protons of 16minor by the phenyl group of the Mosher amide allows the assignment of absolute configuration as shown in Schemes 4 and 5.
PREPARATION OF PHANTASMIDINE AND ANALOGUES THEREOF
-
Page/Page column 30-31, (2012/06/30)
Described are methods of synthesizing phantasmidine and analogues thereof from commercially available starting materials. The compounds are useful as pharmacological probes and potential lead compounds for the development of selective nicotinic receptor therapeutics.